Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation.

Trial Profile

Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 16 Oct 2013 Rescue medication results presented at the 21st United European Gastroenterology Week.
    • 16 Oct 2013 Results reporting rates of diarrhoea presented at the 21st United European Gastroenterology Week.
    • 22 May 2013 Results were presented at the Digestive Disease Week (DDW-2013), and were reported in a Synergy Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top